
Launched on 28 October 2015, the European Commission’s new strategy ‘A Single Market Strategy for Europe – Analysis and Evidence’ proposes a manufacturing waiver during the SPC (Supplementary Protection Certificate) period to allow the European Union generic and biosimilar medicines industries to create up to 64.000 high-tech jobs in the EU and dozens of new companies, with a 3.3 billion euros business value.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze